MDXH MDxHealth: שווי פעילות לרווח לפני ריבית, מסים ופחת

MDxHealth SA (MDXH) sets the standards in prostate tumor detection by integrating genetic screenings into urological practice to reduce unnecessary invasive procedures. Serving as a fundamental assessment tool, this price chart with an EV/EBITDA multiple of 0.00 complements data on the proficient Belgian-American management team, which is effectively expanding insurance coverage. Steady cash inflows are driven by physician adoption of the technologies, ensuring a resilient operating cash flow.

This indicator determines the total business value relative to its operating cash flow before depreciation. The calculation combines market capitalization and net debt, allowing for an assessment of the asset's real price inclusive of tax liabilities. Analysis of the enterprise value to EBITDA multiple reveals discrepancies between market price and efficiency. For MDxHealth (MDXH), which has established an unrivaled standard for prostate cancer diagnostics, this metric confirms the stability of the ecosystem's capitalization.